Results 271 to 280 of about 8,994,995 (387)

A millimeter-Sized Robot Using SMA and Its Control

open access: hybrid, 1995
Katsutoshi Kuribayashi, Seiji Shimizu
openalex   +1 more source

Fabrication and characterization of SMA hybrid composites [PDF]

open access: green, 2001
Travis L. Turner   +2 more
openalex   +1 more source

Tumor clusters with divergent inflammation and human retroelement expression determine the clinical outcome of patients with serous ovarian cancer

open access: yesMolecular Oncology, EarlyView.
Analysis of treatment‐naïve high‐grade serous ovarian carcinoma (HGSOC) and control tissues for ERVs, LINE‐1 (L1), inflammation, and immune checkpoints identified five clusters with diverse patient recurrence‐free survivals. An inflammation score was calculated and correlated with retroelement expression, where one novel cluster (Triple‐I) with high ...
Laura Glossner   +6 more
wiley   +1 more source

PLATELET AND NEUTROPHIL DISTRIBUTIONS IN PUMP-OXYGENATOR CIRCUITS. I. INFLUENCE OF “SMA” SURFACE TREATMENT

open access: bronze, 1996
Marco Jessen   +12 more
openalex   +1 more source

Nusinersen for SMA: expanded access programme

open access: yesJournal of Neurology Neurosurgery & Psychiatry, 2018
M. Farrar   +16 more
semanticscholar   +1 more source

A DIA‐MS‐based proteomics approach to find potential serum prognostic biomarkers in glioblastoma patients

open access: yesMolecular Oncology, EarlyView.
A DIA‐MS‐based proteomics analysis of serum samples from GB patients and healthy controls showed that high levels of IL1R2 and low levels of CRTAC1 and HRG in serum are associated with poor survival outcomes for GB patients. These circulating proteins could serve as biomarkers for the prediction of outcome in patients with GB.
Anne Clavreul   +11 more
wiley   +1 more source

Artificial Urethral Valve Using SMA Actuators. Fundamental Principle of Valve and the Verification of Opening/Closing Functions.

open access: bronze, 1998
Seiji CHONAN   +7 more
openalex   +2 more sources

EGFR‐STAT3 activation provides a therapeutic rationale for targeting aggressive ETV1‐positive prostate cancer

open access: yesMolecular Oncology, EarlyView.
Cotargeting EGFR and STAT3 with Erlotinib and TTI‐101 impairs both 2D and 3D growth of ETV1‐overexpressing prostate cancer cells by disrupting a self‐sustaining ETV1–EGFR positive feedback loop that promotes EGFR and STAT3 expression and phosphorylation (activation).
Elsa Gomes Paiva   +5 more
wiley   +1 more source

Home - About - Disclaimer - Privacy